At-Home Molecular Testing Market Revenue is Expected to Reach US$16.3 Billion by the end of 2030, By Persistence Market Research
17 janv. 2024 00h58 HE
|
Persistence Market Research
New York, Jan. 17, 2024 (GLOBE NEWSWIRE) -- At-Home Molecular Testing Market: A Booming Frontier in Healthcare At-Home Molecular Testing refers to the use of molecular diagnostic tests conducted in...
P23 Health E-Commerce Well-Being Company Just Launched in Partnership With P23 Labs, a Renowned Molecular Laboratory
03 nov. 2022 09h15 HE
|
P23 Health
SAVANNAH, Ga., Nov. 03, 2022 (GLOBE NEWSWIRE) -- P23 Health is a newly formed digital healthcare and wellness company under the P23 umbrella. P23 Health's strategic partner is acknowledged molecular...
MAKO Medical Invests in New Laboratory Automation
18 juil. 2022 07h10 HE
|
MAKO Medical
RALEIGH, N.C., July 18, 2022 (GLOBE NEWSWIRE) -- MAKO Medical Laboratories, a national reference laboratory and national leader in COVID-19 testing, is purchasing four additional high-tech liquid...
Genetic Testing Market is projected to reach USD 36.11 Billion by 2030, growing at a CAGR of 10%: Straits Research
16 juin 2022 15h40 HE
|
Straits Research
New York, United States, June 16, 2022 (GLOBE NEWSWIRE) -- Genetic testing examines DNA to find gene mutations linked to a wide range of hereditary illnesses. There are multiple forms of genetic...
Current Signed Customers Expected to Generate $1M Annualized Reported Revenues from Precipio’s HemeScreen POL Offering by Q4-2021
26 avr. 2021 11h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., April 26, 2021 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that currently, the contracted annualized revenues from signed customers...
Precipio Signs Sales & Marketing Agreement for HemeScreen™ with Major Oncology Distributor
10 déc. 2020 10h15 HE
|
Precipio, Inc.
NEW HAVEN, Conn., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) has entered into an agreement with a major US-based oncology distributor to...
Interpace Diagnostics Labs Receive College of American Pathology (CAP) Accreditation
25 avr. 2019 06h55 HE
|
Interpace Diagnostics Group, Inc.
Pennsylvania and Connecticut Labs Both Receive Accreditation PARSIPPANY, NJ, April 25, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it has...
Interpace Diagnostics Announces New York State Approval
23 avr. 2019 06h55 HE
|
Interpace Diagnostics Group, Inc.
State of New York Approves Commercialization of ThyraMIR® Now in Three Specimens PARSIPPANY, NJ, April 23, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today...
In-vitro Diagnostic Services Market worth over $63 billion by 2024: Global Market Insights, Inc.
13 sept. 2018 06h00 HE
|
Global Market Insights, Inc
Sellbyville, Delaware, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Global In-vitro Diagnostic Services Market is poised to cross USD 63 billion by 2024; according to a new research report by Global Market...
Iaslc, 폐암 전문의 대상으로 분자 테스트에 대한 글로벌 서베이 실시
12 juil. 2018 16h11 HE
|
IASLC
미국 덴버, July 13, 2018 (GLOBE NEWSWIRE) -- 국제폐암연구협회(IASLC)가 폐암 환자에 대한 분자 테스트 관련 종사자들을 대상으로 글로벌 서베이를 실시한다. 이번 서베이는 베스트 프랙티스가 시행되고 있는지 평가하고 궁극적으로는 글로벌 분자 테스트 가이드라인을 개발하기 위해 설계되었다. IASLC Global Survey on...